The SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Clinical Trials - New Agents series contains four modules.
Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies
Peter Ellmark, PhD - Alligator Bioscience
Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents
James L. Gulley, MD, PhD, FACP - National Cancer Institute
Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors
Glen J. Weiss, MD - Western Regional Medical Center Inc.
Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance
Jason Williams, BS - University of Chicago
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
Course Objectives Upon completion of this activity, participants will be able to:
Describe the immune mechanisms that new immunotherapy agents are targeting.
Outline how new IO agents work to circumvent cancer immune resistance mechanisms.
Define the immune response generated by new IO agents.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Cookies are small pieces of information that are stored by your browser on your computerâ€™s hard drive.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
For more information, including instructions on how to remove the cookies that have been placed,